TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
ARPA-H has awarded up to $51.7 million to SEEDS, a four-year research consortium co-led by the Buck Institute and Georgetown University. The team will combine experiments and computational modeling to study how intrinsically disordered proteins change in different cellular environments, initially focusing on Alzheimer’s disease and Ewing sarcoma. The work aims to improve early detection and inform future treatments, but it has not yet produced a diagnostic or therapy.
The Advanced Research Projects Agency for Health (ARPA-H) has awarded up to $51.7 million to a four-year research consortium co-led by the Buck Institute for Research on Aging and Georgetown University to study how disease-linked proteins begin changing shape. The project, called SEEDS, will combine computational predictions with laboratory experiments, initially examining proteins associated with Alzheimer’s disease and Ewing sarcoma.
SEEDS stands for Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale. It brings together researchers from nine academic institutions and seven industry partners, combining expertise in protein science, artificial intelligence, computational modeling, cancer and neuroscience. Georgetown’s Priyanka Joshi and the Buck Institute’s Chuankai (Kai) Zhou are co-leading the consortium.
The team will study intrinsically disordered proteins, or IDPs, which do not settle into one stable three-dimensional shape. Their forms and behavior can shift with cellular conditions such as acidity, molecular crowding, metals, metabolites and chemical modifications. These proteins serve functions in healthy cells, but some are associated with disease when their behavior changes or they aggregate.
Rather than rely on models alone, researchers plan to compare physics-guided AI predictions with experimental measurements made under different conditions. The project’s stated aim is to learn how protein sequences and cellular surroundings relate to behavior, then use that knowledge to develop ways to detect or potentially redirect harmful changes. The award is described as being worth up to $51.7 million; the source does not specify how much will ultimately be disbursed.
Why Early Protein Changes Matter
Many proteins linked to neurodegenerative disease and cancer are difficult to target with conventional drug-design approaches. Unlike proteins with stable structures and clear binding pockets, IDPs can occupy many shapes, making it harder to identify a single structure for a medicine to bind. The consortium is therefore focusing on how these proteins behave across changing cellular conditions, rather than treating them as fixed shapes.
The research targets a stage that may precede visible clumping and lasting cellular injury. If the team can reliably identify protein behavior associated with disease before damage occurs, that could help guide future diagnostic tools or interventions. Those are project goals, not established outcomes: the announcement does not report a validated test, an effective treatment or evidence that the proposed approach can prevent disease.
Products Worth Considering
eufy E25 Robot Vacuum and Mop Combo with HydroJet Roller Mop
Bose Lifestyle Ultra Wireless Home Speaker
Philips Hue Bridge Pro Smart Lighting Hub
As an affiliate, we earn on qualifying purchases.
The BIOGAMI Research Framework
SEEDS is part of ARPA-H’s BIOmolecular Grammar for protein Aggregation Modulation and Intervention program, known as BIOGAMI. The program focuses on the early stages of protein dysfunction, before misfolding or aggregation causes lasting damage. Its “molecular grammar” framing refers to the effort to identify rules linking a protein’s sequence and environment to its behavior.
AI tools such as AlphaFold have advanced protein science by learning from large collections of structural data. But, according to the source report, researchers have less structural information for intrinsically disordered proteins, complicating efforts to predict their behavior. SEEDS aims to build the data and methods needed to study them at scale while examining selected proteins in greater detail. The consortium draws on two research teams, Georgetown’s INTREPID and the Buck Institute’s SHIFT.
“We aim to uncover the principles that determine when these proteins remain in healthy functional ensembles and when they begin to shift toward disease-associated states.”
— Chuankai (Kai) Zhou, assistant professor at the Buck Institute
What the Project Has Yet to Show
The award announcement describes a research plan, not a completed discovery. It does not identify all target proteins, specify the experiments or milestones in detail, or report a model that can already predict when a protein will turn harmful. The accuracy and practical limits of the planned predictions remain to be tested against experimental results.
It is also unclear when any findings might lead to clinical tests or treatments, or whether the work will produce tools that prove useful in patients. The initial focus on Alzheimer’s disease and Ewing sarcoma does not establish that the approach will work across those diseases or other conditions linked to protein misfolding. ARPA-H’s award is for up to $51.7 million, and the source report does not clarify the final amount or payment schedule.
Four Years of Model Testing
During the four-year project, SEEDS researchers plan to build and test models of protein behavior by pairing computational predictions with measurements under varied cellular conditions. The first research focus is Alzheimer’s disease and Ewing sarcoma, while the consortium’s broader goal is to develop a platform for studying disease-associated protein changes.
The next meaningful updates will be evidence that the models predict protein behavior reliably in experiments, along with details about the proteins and conditions tested. Any claims about diagnostic or treatment applications will require further development and validation; the announcement does not give dates for those steps.
Key Questions
What is the SEEDS project?
SEEDS is a four-year research consortium co-led by the Buck Institute and Georgetown University. It will study how intrinsically disordered proteins behave as their cellular environment changes, using computational models and experiments.
How much funding did the consortium receive?
ARPA-H awarded the project up to $51.7 million. The available report does not state the final amount to be paid or the award’s payment schedule.
Which diseases are the initial focus?
The project’s initial focus is Alzheimer’s disease and Ewing sarcoma. The announcement also refers to protein misfolding in ALS, some cancers and other conditions, but does not say those are initial SEEDS targets.
Does the award mean a new treatment is available?
No. The award funds research intended to improve understanding and potentially support future diagnostics or treatments. No new diagnostic or treatment is reported as having been developed or tested in patients.
Source: rss
